Recently, Beyang Therapeutics Co., Ltd. (hereinafter referred to as "Beyang Therapeutics") announced that it has secured tens of millions of yuan in Pre-A+ round financing. This round was exclusively invested by Yuanjin Venture Capital, and the funds raised will be used to accelerate the (China-US) IND registration and application research for the first two pipelines promoted by Beyang Therapeutics in the fields of ophthalmology and oncology.
It is reported that Beyang Therapeutics was founded in April 2021, with its headquarters located in the BioBAY biopharmaceutical park in Suzhou Industrial Park, China. The company has built the ExCEED technology platform, which strengthens early-stage drug discovery capabilities by integrating computational modeling with wet-lab techniques across three core areas: molecular design, drug-likeness optimization, and biological evaluation.
The core team members of Beyang Therapeutics have an average of over 20 years of practical experience in combining new drug research and development with computational simulation in pharmaceutical companies both in China and abroad. They have cumulatively participated in the research and development of more than 20 clinical-stage drug candidates or newly approved drugs. The company focuses on ophthalmology and oncology, and has independently developed multiple project pipelines. The first two projects (BT01001 and BT01002) have fully demonstrated Best-in-Class potential in preclinical head-to-head studies and are currently advancing in (U.S.-China) IND registration and application research.
Since its establishment, Beyang Therapeutics has completed multiple rounds of financing, including a Pre-A round led by Juming Venture Capital in May 2023.
Hu Qiyue, founder of Beyang Therapeutics, stated: The project pipeline built on the ExCEED technology platform is accelerating in delivering value, fully demonstrating Best-in-Class potential. In the future, while fully advancing the development of our own pipeline, we will also expand external collaborations to provide doctors, patients, and partners with innovative drugs of greater clinical value, striving to make Beyang Therapeutics an innovative dream factory for new drug research and development.